Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices

Head and Neck

Volumn 38, Issue , 2016, Pages E911-E915

  Peria, Marine ^a   Donnadieu, Jérôme ^a   Racz, Caroline ^a   Ikoli, Jean Fortuné ^a   Galmiche, Antoine ^a,b   Chauffert, Bruno ^a,b   Page, Cyril ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

cellular culture; cetuximab; head and neck squamous cell carcinoma; head and neck surgery; oral oncology

Indexed keywords

CETUXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER SURGERY; CELL PROLIFERATION; DRUG EFFICACY; DRUG SENSITIVITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; HEAD AND NECK TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CETUXIMAB; HEAD AND NECK NEOPLASMS; HUMANS; TUMOR CELLS, CULTURED;

EID: 84939205150     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.24126     Document Type: Article

References (13)

1. Vermorken JB, Mesia R, Rivera F, et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
2. Bonner JA, Harari PM, Giralt J, et al., Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
3. Cooper JB, Cohen EE,. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck 2009; 31: 1086-1094.
4. Godin C, Dupont S, Ezzoukhry Z, et al., Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Anticancer Res 2013; 33: 1415-1420.
5. Bhatt VR, Ganti AK,. Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. Future Oncol 2014; 10: 17-20.
6. Ezzoukhry Z, Louandre C, Trécherel E, et al., EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012; 131: 2961-2969.
7. Holliday DL, Moss MA, Pollock S, et al., The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol 2013; 66: 253-255.
8. Sobral RA, Honda ST, Katayama ML, et al., Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer. Acta Vet Scand 2008; 50: 27.
9. van der Kuip H, Mürdter TE, Sonnenberg M, et al., Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006; 6: 86.
10. Merz F, Gaunitz F, Dehghani F, et al., Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol 2013; 15: 670-681.
11. Vaira V, Fedele G, Pyne S, et al., Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A 2010; 107: 8352-8356.
12. Grosso SH, Katayama ML, Roela RA, et al., Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res 2013; 352: 671-684.
13. Gerlach MM, Merz F, Wichmann G, et al., Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer 2014; 110: 479-488.